Product Information
BUPRENORPHINE 8 MG TABLET SL is a generic product labeled by Sun Pharmaceutical Industries Inc., priced at $0.5714 per EA under NDC 62756046083. Its NADAC has been published 458 times since Dec 27, 2017.
FDA first approved this application on Jan 29, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
8 mg/1
Manufacturer
Sun Pharmaceutical Industries Inc.NDC
62756046083
Classification
Generic
Dosage Form
TABLET
Route
SUBLINGUAL
Effective Date
9/23/2026
Active Ingredients
BUPRENORPHINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA201760FDA Approved
1/29/2016
TE Code
AB
On Market Since
2/17/2016
Pharmacological Classes
Price Statistics
The NADAC for BUPRENORPHINE 8 MG TABLET SL has been published 458 times since Dec 27, 2017, and over the history we have for it it has declined 58.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.5714 per EA |
|---|---|
| All-time high | $1.3718 (Jan 10, 2018) |
| All-time low | $0.5567 (Apr 22, 2026) |
| 52-week high | $0.7127 |
| 52-week low | $0.5567 |
| Median price | $0.8511 |
| Average price | $0.8760 |
| Largest weekly change | +27.5% (Aug 21, 2024) |
| Weeks tracked | 458 |
| Tracking since | Dec 27, 2017 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Sun Pharmaceutical Industries Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Buprenorphine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Partial Opioid Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BUPRENORPHINE 8 MG TABLET SL?
The current National Average Drug Acquisition Cost (NADAC) for BUPRENORPHINE 8 MG TABLET SL, manufactured by Sun Pharmaceutical Industries Inc., is $0.5714 per EA (NDC 62756046083), effective Sep 30, 2026.
How has the price of BUPRENORPHINE 8 MG TABLET SL changed over time?
Over the history we have for it, the NADAC for BUPRENORPHINE 8 MG TABLET SL has declined 58.3%. It has been tracked across 458 weekly CMS publications since Dec 27, 2017.
What are the highest and lowest recorded NADAC prices for BUPRENORPHINE 8 MG TABLET SL?
Since Dec 27, 2017, the NADAC for BUPRENORPHINE 8 MG TABLET SL has ranged from a low of $0.5567 (Apr 22, 2026) to a high of $1.3718 (Jan 10, 2018), with a median of $0.8511 per EA.
Are there cheaper alternatives to BUPRENORPHINE 8 MG TABLET SL?
5 manufacturers publish a NADAC-priced product with the same active ingredient and strength as BUPRENORPHINE 8 MG TABLET SL in a comparable dosage form, but none are currently priced below it.
Who manufactures BUPRENORPHINE 8 MG TABLET SL?
BUPRENORPHINE 8 MG TABLET SL (NDC 62756046083) is labeled by Sun Pharmaceutical Industries Inc., and CMS classifies it as a generic product.